Skip to main content
. Author manuscript; available in PMC: 2020 Jun 12.
Published in final edited form as: Curr Cancer Drug Targets. 2009 Mar;9(2):189–201. doi: 10.2174/156800909787580971

Fig. 5. Comparison of SC21- and SC23-mediated signaling pathways using bioinformatics tools.

Fig. 5.

(A). The Kinex™ antibody microarray of SC21- and SC23-treated MDA-MB-435 cell lysates. MDA-MB-435 cells were treated with 0.1 μM and 1 μM of SC21 and SC23, respectively, for 24 h. The total proteins were harvested and subjected to 628-protein microarray analysis using Kinexus™ Kinex antibody microarray platform. (B). Ingenuity pathway network of SC21 (score 39) obtained on a set of altered proteins. Proteins with their ratio changes and corresponding Swiss-Prot accession numbers were uploaded into IPA software. —: Direct interaction; - - - -: Indirect interaction. (C). Ingenuity pathway network of SC23 (score 41) obtained on a set of altered proteins. Proteins with their ratio changes and corresponding Swiss-Prot accession numbers were uploaded into IPA software. —: Direct interaction; - - - -: Indirect interaction. (D). Biological function comparison of SC21 and SC23. The biological functions of SC21 and SC23 were compared with IPA comparison analysis. 16 biological functions of interest were selected. 1. Cell death, 2. Cell cycle, 3. Cancer, 4. Cellular growth and proliferation, 5. DNA replication, recombination and repair, 6. Post-translational modification, 7. Small molecule biochemistry, 8. Cellular development, 9. Molecular transport, 10. Cell morphology, 11. Gene expression, 12. Cellular movement, 13. Cell signaling, 14. Immunological disease, 15. Cell-cell signaling and interaction, 16. Drug metabolism.